Source 1primary paper2025MED
Toolkit/mass spectrometric analysis
mass spectrometric analysis
Taxonomy: Technique Branch / Method. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Mass spectrometric analysis revealed a substantial decrease in contaminants, with VLP-specific proteins comprising >90% of the final product.
Usefulness & Problems
Why this is useful
Mass spectrometric analysis was used to evaluate the composition of the purified VLP product. In this study it supported the claim that contaminants decreased and VLP-specific proteins exceeded 90% of the final product.; assessing contaminant reduction in purified VLP preparations; measuring VLP-specific protein composition in final product
Source:
Mass spectrometric analysis was used to evaluate the composition of the purified VLP product. In this study it supported the claim that contaminants decreased and VLP-specific proteins exceeded 90% of the final product.
Source:
assessing contaminant reduction in purified VLP preparations
Source:
measuring VLP-specific protein composition in final product
Problem solved
It provides an analytical readout for purity and protein composition after purification. This helps verify whether the purification workflow enriches for VLP-associated material over contaminants.; characterizing purity and composition of VLP preparations
Source:
It provides an analytical readout for purity and protein composition after purification. This helps verify whether the purification workflow enriches for VLP-associated material over contaminants.
Source:
characterizing purity and composition of VLP preparations
Problem links
characterizing purity and composition of VLP preparations
LiteratureIt provides an analytical readout for purity and protein composition after purification. This helps verify whether the purification workflow enriches for VLP-associated material over contaminants.
Source:
It provides an analytical readout for purity and protein composition after purification. This helps verify whether the purification workflow enriches for VLP-associated material over contaminants.
Published Workflows
Objective: Develop a scalable, broadly applicable purification workflow for genome-editing VLPs that improves purity, integrity, biological activity, and therapeutic efficacy.
Why it works: The workflow was developed around characteristic properties of MLV-derived engineered VLPs and HIV-derived engineered nucleocytosolic vehicles, and uses chromatographic steps to deplete contaminants while improving VLP integrity and biological activity.
removal of host cell proteinsremoval of cell-culture contaminantspreservation or improvement of VLP integritysingle-modal chromatographymultimodal chromatographymass spectrometric analysisin vivo evaluation
Stages
- 1.Single-modal chromatographic purification(secondary_characterization)
This stage is part of the developed purification workflow intended to improve product quality over ultracentrifugation-based methods.
Selection: chromatographic purification of genome-editing VLPs based on their characteristic properties
- 2.Multimodal chromatographic purification(secondary_characterization)
This stage contributes to the scalable purification platform that yields higher-quality VLPs than conventional ultracentrifugation.
Selection: further chromatographic purification to remove contaminants and improve final VLP quality
- 3.Mass spectrometric composition analysis(confirmatory_validation)
This stage confirms that the purification workflow substantially decreases contaminants and enriches VLP-specific proteins.
Selection: assessment of contaminant reduction and VLP-specific protein enrichment in the final product
- 4.In vivo therapeutic evaluation(in_vivo_validation)
This stage validates that improved purification quality is associated with improved therapeutic outcomes in vivo.
Selection: testing whether chromatographically purified VLPs improve therapeutic outcomes in vivo
Taxonomy & Function
Primary hierarchy
Technique Branch
Method: A concrete measurement method used to characterize an engineered system.
Techniques
Functional AssayTarget processes
recombinationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor
Operational role: sensor. Implementation mode: genetically encoded. Cofactor status: cofactor requirement unknown.
Independent follow-up evidence is still limited. Validation breadth across biological contexts is still narrow. Independent reuse still looks limited, so the evidence base may be fragile. No canonical validation observations are stored yet, so context-specific performance remains under-specified.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Chromatographically purified VLPs have superior protein composition, consistency, and functional delivery compared with VLPs partially purified by conventional ultracentrifugation.
Ultracentrifugation-based purification approaches for VLPs suffer from inconsistent product quality and poor scalability.
In vivo studies confirmed improved therapeutic outcomes when chromatographically purified VLPs were used.
Mass spectrometric analysis showed that VLP-specific proteins comprised more than 90% of the final purified product.
VLP-specific proteins in final product 90 %
The chromatographic workflow removes host cell proteins and cell-culture contaminants while improving VLP integrity and biological activity.
A broadly applicable chromatography-based purification strategy improves the purity and therapeutic efficacy of genome-editing VLPs.
Clinical translation of VLP vectors is hindered by inadequate purification methods.
Approval Evidence
1 source1 linked approval claimfirst-pass slug mass-spectrometric-analysis
Mass spectrometric analysis revealed a substantial decrease in contaminants, with VLP-specific proteins comprising >90% of the final product.
Source:
measurement resultsupports
Mass spectrometric analysis showed that VLP-specific proteins comprised more than 90% of the final purified product.
Source:
Comparisons
Source-backed strengths
provided compositional evidence for contaminant reduction
Source:
provided compositional evidence for contaminant reduction
Compared with barcoded Cre recombinase mRNA barcode platform
mass spectrometric analysis and barcoded Cre recombinase mRNA barcode platform address a similar problem space because they share recombination.
Shared frame: same top-level item type; shared target processes: recombination
Compared with calcium imaging
mass spectrometric analysis and calcium imaging address a similar problem space because they share recombination.
Shared frame: same top-level item type; shared target processes: recombination
Relative tradeoffs: appears more independently replicated.
Compared with two-photon excitation microscopy
mass spectrometric analysis and two-photon excitation microscopy address a similar problem space because they share recombination.
Shared frame: same top-level item type; shared target processes: recombination
Strengths here: looks easier to implement in practice.
Ranked Citations
- 1.